Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
cardiac glycoside |
| gptkbp:approvedBy |
1954
|
| gptkbp:ATCCode |
C01AA05
|
| gptkbp:bioavailability |
60-80%
|
| gptkbp:brand |
gptkb:Lanoxin
|
| gptkbp:CASNumber |
20830-75-5
|
| gptkbp:contraindication |
gptkb:ventricular_fibrillation
|
| gptkbp:derivedFrom |
gptkb:Digitalis_lanata
|
| gptkbp:discoveredBy |
gptkb:William_Withering
|
| gptkbp:effect |
increases cardiac contractility
slows heart rate |
| gptkbp:eliminationHalfLife |
36-48 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:hasMolecularFormula |
C41H64O14
|
| https://www.w3.org/2000/01/rdf-schema#label |
Digoxin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits Na+/K+ ATPase
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
25%
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
gptkb:arrhythmia
nausea vomiting visual disturbances |
| gptkbp:usedFor |
gptkb:atrial_fibrillation
heart failure |
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:Glycoside
|
| gptkbp:bfsLayer |
7
|